Initial Study of Rituximab to Treat Primary Biliary Cirrhosis
Status:
Completed
Trial end date:
2009-12-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine the safety of the anti-CD20 antibody rituximab in
treating patients with Primary Biliary Cirrhosis (PBC). Rituximab is a laboratory-made
antibody currently used to treat some kinds of lymphoma. Rituximab may also help people with
PBC, a disease of the immune system. However, the safety of rituximab in PBC patients must
first be established.